

008P1P1C1C2C1

OMBIPATENT DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY

U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

ATTORNEY DOCKET NO.: 044481-5001-14-US

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

AGENTS AFFECTING THROMBOSIS AND HEMOSTASIS

the specification of which:

is attached hereto; or

was filed as United States application Serial No. 09/362,207 on July 28, 1999 and was amended on _____ (if applicable); or

was filed as PCT international application Number _____ on _____ and was amended under PCT Article 19 on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the U.S. Patent and Trademark Office information which is material to the patentability of claims presented in this application in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate or §365(a) of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

PRIOR FOREIGN APPLICATION(S):

COUNTRY (if PCT, indicate PCT)	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No

I hereby claim the benefits under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

U.S. PROVISIONAL APPLICATIONS

U.S. PROVISIONAL APPLICATION NO.

U.S. FILING DATE

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) or §365(c) of any PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me to be material to the patentability of claims presented in this application in accordance with Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application(s) and the national or PCT international filing date of this application:

PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT:

U.S. APPLICATIONS		STATUS (Check One)		
U.S. APPLICATION NO.	U.S. FILING DATE	PATENTED	PENDING	ABANDONED
07/578,646	September 4, 1990	X		
07/808,329	December 16, 1991			X
08/249,777	May 26, 1994	X		
08/268,003	June 29, 1994	X		
08/469,301	June 6, 1995	X		
09/016,403	January 30, 1998	X		

POWER OF ATTORNEY: As a named inventor, I hereby appoint the registered practitioners of Morgan, Lewis & Bockius LLP included in the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number.

Customer Number: 009629


Direct Telephone Calls To:
(name and telephone number)

Reid G. Adler
202-467-7756

Combined Declaration For Patent Application and Power of Attorney - (Continued)
(includes Reference to PCT International Applications)

ATTORNEY DOCKET NO.: 044481-5002-14-US

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

FULL NAME OF SOLE OR FIRST INVENTOR	David L. WOLF	
RESIDENCE & CITIZENSHIP	Davis, CA 95616	COUNTRY OF CITIZENSHIP United States
POST OFFICE ADDRESS	3133 Woods Circle, Davis, CA 95616, U.S.A.	
FIRST OR SOLE INVENTOR'S SIGNATURE		DATE 8-28-00
FULL NAME OF SECOND INVENTOR	Uma SINHA	
RESIDENCE & CITIZENSHIP	San Francisco, CA 94127	COUNTRY OF CITIZENSHIP India
POST OFFICE ADDRESS	808 Junipero Serra Boulevard, San Francisco, CA 94127	
SECOND INVENTOR'S SIGNATURE		DATE

Listing of Inventors Continued on attached page(s) [] Yes [X] No

008P1F1C122C1

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY

U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

ATTORNEY DOCKET NO.: 044481-5001-1

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

AGENTS AFFECTING THROMBOSIS AND HEMOSTASIS

the specification of which:

is attached hereto; or

was filed as United States application Serial No. 09/362,207 on July 28, 1999 and was amended on _____ (if applicable); or

was filed as PCT international application Number _____ on _____ and was amended under PCT Article 19 on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the U.S. Patent and Trademark Office information which is material to the patentability of claims presented in this application in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate or §365(a) of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having filing date before that of the application(s) of which priority is claimed:

PRIOR FOREIGN APPLICATION(S):

COUNTRY (if PCT, indicate PCT)	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No

I hereby claim the benefits under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

U.S. PROVISIONAL APPLICATIONS

U.S. PROVISIONAL APPLICATION NO.	U.S. FILING DATE

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) or §365(c) of any PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me to be material to the patentability of claims presented in this application in accordance with Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application(s) and the national or PCT international filing date of this application:

PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT:

U.S. APPLICATIONS		STATUS (Check One)		
U.S. APPLICATION NO.	U.S. FILING DATE	PATENTED	PENDING	ABANDONED
07/578,646	September 4, 1990	X		
07/808,329	December 16, 1991			X
08/249,777	May 26, 1994	X		
08/268,003	June 29, 1994	X		
08/469,301	June 6, 1995	X		
09/016,403	January 30, 1998	X		

POWER OF ATTORNEY: As a named inventor, I hereby appoint the registered practitioners of Morgan, Lewis & Bockius LLP included in the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number.

Customer Number: 009629

Direct Telephone Calls To:
(name and telephone number)

Reid G. Adler
202-467-7756

Combined Declaration For Patent Application and Power of Attorney - (Continued)
(includes Reference to PCT International Applications)

ATTORNEY DOCKET NO.: 044481-5002-14-US

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

FULL NAME OF SOLE OR FIRST INVENTOR	David L. WOLF	
RESIDENCE & CITIZENSHIP	Davis, CA 95616	COUNTRY OF CITIZENSHIP United States
POST OFFICE ADDRESS	3133 Woods Circle, Davis, CA 95616, U.S.A.	
FIRST OR SOLE INVENTOR'S SIGNATURE		DATE
FULL NAME OF SECOND INVENTOR	Uma SINHA	
RESIDENCE & CITIZENSHIP	San Francisco, CA 94127	COUNTRY OF CITIZENSHIP India
POST OFFICE ADDRESS	808 Junipero Serra Boulevard, San Francisco, CA 94127	
SECOND INVENTOR'S SIGNATURE <i>Uma Sinha</i>		DATE 8/31/00

Listing of Inventors Continued on attached page(s) ☐ Yes ☒ No



MST
PAT84

AUGUST 13, 2002

PTAS

Chief Information Officer
Washington, DC 20231
www.uspto.gov

MORGAN, LEWIS & BOCKIUS LLP
MICHAEL S. TUSCAN P.H.
1111 PENNSYLVANIA AVE., NW
WASHINGTON, D.C. 20004



102122836A

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 06/10/2002

REEL/FRAME: 012977/0516
NUMBER OF PAGES: 7

BRIEF: MERGER (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:
COR THERAPEUTICS, INC.

DOC DATE: 02/12/2002

ASSIGNEE:
MILLENNIUM PHARMACEUTICALS, INC.
75 SIDNEY STREET
CAMBRIDGE, MASSACHUSETTS 02139

SERIAL NUMBER: 07808329 44481-5000-01
PATENT NUMBER:

FILING DATE: 12/16/1991
ISSUE DATE:

mst/mst/rjs
Abandoned

SERIAL NUMBER: 08477133 44481-5002-06
PATENT NUMBER:

FILING DATE: 06/07/1995
ISSUE DATE:

mst/mst/rjs
Lapsed

SERIAL NUMBER: 09362207 44481-5002-14
PATENT NUMBER:

FILING DATE: 07/28/1999
ISSUE DATE:

mst/mst/rjs
Abandoned

SERIAL NUMBER: 09671346 44481-5002-15
PATENT NUMBER:

FILING DATE: 09/27/2000
ISSUE DATE:

mst/mst/rjs

AUG 19 2002

MORGAN, LEWIS & BOCKIUS LLP

DOCKETED

By Saw Date 9/4/02

SERIAL NUMBER: 07854109	44481-5004	FILING DATE: 03/20/1992	MST/MST/RJS
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 08475262	44481-5004-02	FILING DATE: 06/07/1995	MST/MST/RJS
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09621004	44481-5004-04	FILING DATE: 07/20/2000	MST/MST/RJS
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 08390301	44481-5006-01	FILING DATE: 01/25/1995	MST/MST/RK
PATENT NUMBER:		ISSUE DATE:	Abandoned
SERIAL NUMBER: 08474414	44481-5006-02	FILING DATE: 06/07/1995	MST/MST/RK
PATENT NUMBER:		ISSUE DATE:	Abandoned
SERIAL NUMBER: 08486673	44481-5006-06	FILING DATE: 06/07/1995	MST/MST/RK
PATENT NUMBER: 6297026		ISSUE DATE: 10/02/2001	Closed
SERIAL NUMBER: 10127691	44481-5006-09	FILING DATE: 04/23/2002	MST/MST/RK
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09035135	44481-5007-04	FILING DATE: 03/05/1998	MST/ECW/RJS
PATENT NUMBER:		ISSUE DATE:	Abandoned
SERIAL NUMBER: 09801089	44481-5008-02	FILING DATE: 03/08/2001	MST/MST/RJS
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09410738	44481-5010-02	FILING DATE: 10/01/1999	MST/MST/RK
PATENT NUMBER:		ISSUE DATE:	Abandoned
SERIAL NUMBER: 09947922	44481-5010-03	FILING DATE: 09/07/2001	MST/MST/RK
PATENT NUMBER:		ISSUE DATE:	Abandoned
SERIAL NUMBER: 07801795	44481-5011	FILING DATE: 12/02/1991	MST/MST/RJS
PATENT NUMBER:		ISSUE DATE:	Abandoned
SERIAL NUMBER: 08253440	44481-5017-01	FILING DATE: 06/07/1994	MST/MST/RJS
PATENT NUMBER:		ISSUE DATE:	Abandoned
SERIAL NUMBER: 09419076	44481-5017-07	FILING DATE: 10/15/1999	MST/MST/RJS
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09585410	44481-5017-05	FILING DATE: 06/02/2000	MST/MST/RJS
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 08089455	44481-5018	FILING DATE: 07/09/1993	MST/ECW/RJS
PATENT NUMBER:		ISSUE DATE:	Abandoned
SERIAL NUMBER: 08884571	44481-5018-03	FILING DATE: 06/27/1997	MST/ECW/RJS
PATENT NUMBER:		ISSUE DATE:	Abandoned
SERIAL NUMBER: 09560814	44481-5018-04	FILING DATE: 04/28/2000	MST/ECW/RJS
PATENT NUMBER:		ISSUE DATE:	

SERIAL NUMBER: 09991888	44481-5025-03	FILING DATE: 11/26/2001	MST/MST/RJS
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09473716	44481-5027-01	FILING DATE: 12/29/1999	MST/MST/RK
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09474076	44481-5028-01	FILING DATE: 12/29/1999	MST/MST/RK
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 10071223	44481-5029-02	FILING DATE: 02/11/2002	MST/MST/RK
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 08975653	44481-5039-02	FILING DATE: 11/21/1997	MST/MST/RJS
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09673302	44481-5043	FILING DATE: 03/23/2001	MST/ECW/SEZ
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09775803	44481-5044-01	FILING DATE: 02/05/2001	MST/ECW/SEZ
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09745842	44481-5053	FILING DATE: 12/26/2000	MST/MST/EDL
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 08948672	44481-5012	FILING DATE: 10/10/1997	
PATENT NUMBER: 6262047		ISSUE DATE: 07/17/2001	Transfer to T+T+C
SERIAL NUMBER: 09500231	44481-5015	FILING DATE: 02/08/2000	
PATENT NUMBER:		ISSUE DATE:	Transfer to T+T+C
SERIAL NUMBER: 09664535	44481-5041-99	FILING DATE: 09/18/2000	--- T+T+C JAL/ECW/ECW ABANDONED
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09663420	44481-5041	FILING DATE: 09/15/2000	
PATENT NUMBER:		ISSUE DATE:	Transferred to T+T+C
SERIAL NUMBER: 10126976	44481-5041-02	FILING DATE: 04/22/2002	
PATENT NUMBER:		ISSUE DATE:	Transferred to T+T+C
SERIAL NUMBER: 09226103	44481-5042	FILING DATE: 01/07/1999	
PATENT NUMBER:		ISSUE DATE:	Transferred to T+T+C
SERIAL NUMBER: 09501370	44481-5045	FILING DATE: 02/11/2000	
PATENT NUMBER:		ISSUE DATE:	Transferred to T+T+C
SERIAL NUMBER: 09501371	44481-5045-01	FILING DATE: 02/11/2000	
PATENT NUMBER: 6399627		ISSUE DATE: 06/04/2002	Transferred to T+T+C
SERIAL NUMBER: 09576637	44481-5046	FILING DATE: 05/24/2000	
PATENT NUMBER:		ISSUE DATE:	Transferred to T+T+C
SERIAL NUMBER: 09576634	44481-5046-01	FILING DATE: 05/24/2000	
PATENT NUMBER:		ISSUE DATE:	Transferred to T+T+C

SERIAL NUMBER: 09576638	44481-5047	FILING DATE: 05/24/2000	Transferred to T+T+C
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09577131	44481-5047-01	FILING DATE: 05/24/2000	Transferred to T+T+C
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09576635	44481-5048	FILING DATE: 05/20/2000	Transferred to T+T+C
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09576636	44481-5048-01	FILING DATE: 05/24/2000	Transferred to T+T+C
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09576633	44481-5049	FILING DATE: 05/24/2000	Transferred to T+T+C
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09576632	44481-5049-01	FILING DATE: 05/24/2000	Transferred to T+T+C
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09577154	44481-5049-02	FILING DATE: 05/24/2000	Transferred to T+T+C
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09636804	44481-5050	FILING DATE: 08/10/2000	Transferred to T+T+C
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09662807	44481-5051	FILING DATE: 09/15/2000	Transferred to T+T+C
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09794214	44481-5051-01	FILING DATE: 02/28/2001	Transferred to T+T+C
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09714532	44481-5052	FILING DATE: 11/17/2000	Transferred to T+T+C
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09773383	44481-5055	FILING DATE: 02/01/2001	Transferred to T+T+C
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09773372	44481-5056	FILING DATE: 02/01/2001	Transferred to T+T+C
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09773373	44481-5057	FILING DATE: 02/01/2001	Transferred to T+T+C
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09773374	44481-5058	FILING DATE: 02/01/2001	Transferred to T+T+C
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09773375	44481-5059	FILING DATE: 02/01/2001	Transferred to T+T+C
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09775812	44481-5060	FILING DATE: 02/05/2001	Transferred to T+T+C
PATENT NUMBER:		ISSUE DATE:	
SERIAL NUMBER: 09920325	44481-5060-01	FILING DATE: 08/02/2001	Transferred to T+T+C
PATENT NUMBER:		ISSUE DATE:	

012977/0516 PAGE 5

SERIAL NUMBER: 09816782 44481-5062
PATENT NUMBER:

FILING DATE: 03/26/2001 Transferred
ISSUE DATE: TO T+TC


SERIAL NUMBER: 09816771 44481-5063
PATENT NUMBER:

FILING DATE: 03/26/2001 Transferred to
ISSUE DATE: T+TC

SERIAL NUMBER: 09816781 44481-5064
PATENT NUMBER:

FILING DATE: 03/26/2001 Transferred
ISSUE DATE: T+TC

TARA WASHINGTON, EXAMINER
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS



06-14-2002

FORM PTO-1595
(Rev. 6-93)



RECORDATION FOR COVER SHEET
102122836
PATENTS ONLY

MENT OF COMMERCE
ent and Trademark Office

Attorney Docket No.: 44481-0021-US

To the Assistant Commissioner for Patents:
Please record the attached original documents or copy thereof.

ATTN: BOX ASSIGNMENT

1. Name of conveying party(ies):

COR Therapeutics, Inc.

6-10-02

Additional name(s) of conveying party(ies) attached?

Yes ☒ No

2. Name and address of receiving party(ies):

Name: Millennium Pharmaceuticals, Inc.

Street Address: 75 Sidney Street

City: Cambridge State: MA

Country: US Zip: 02139

Additional name(s) & address(es) attached?

Yes ☒ No

3. Nature of conveyance:

☐ Assignment ☒ Merger
☐ Security Agreement ☐ Change of Name
Other _____

Execution Date(s): February 12, 2002

4. Application number(s) or patent number(s):

If this document is being filed together with a new application the execution date of the application is:

A. Patent Application No.(s): 07/808,329

B. Patent No.(s)

Additional numbers attached: ☒ Yes ☐ No See attached Schedule B.

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Michael S. Tuscan, Ph.D.
Internal Address: Customer No. 009629
Morgan, Lewis & Bockius LLP

Street Address: 1111 Pennsylvania Ave., NW
City: Washington State: D.C. Zip: 20004

6. Total number of applications and patents involved: 61

7. Total fee (37 C.F.R. §3.41): \$2440.00

☐ Enclosed

☒ Authorized to be charged to deposit account 50-0310

8. Deposit account number: 50-0310

Attach duplicate of page if paying by deposit account

9. Statement and Signature

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Michael S. Tuscan, Ph.D., Reg. No. 43,210

Name of Person Signing

6/13/2002 DBYRNE 00000040 500310 07808329

FL:581 2440.00 \$11

Signature

Date

Total number of pages including cover sheet, attachments and documents: 8

Schedule B, U.S. applications

Application No.	Filing Date	Title	Ref. No.
07/808,329	1991-12-16	Antithrombosis agents	44481-5002-01
08/477,133	1995-06-07	Agents affecting thrombosis and hemostasis	44481-5002-06
09/362,207	1999-07-28	Agents affecting thrombosis and hemostasis	44481-5002-14
09/671,346	2000-09-27	Agents affecting thrombosis and hemostasis	44481-5002-15
07/854,109	1992-03-20	Glycosylation-mediated inhibition of Factor X	44481-5004
08/475,262	1995-06-07	Glycosylation-mediated inhibition of Factor X	44481-5004-02
09/621,004	2000-07-20	Glycosylation-mediated inhibition of Factor X	44481-5004-04
08/390,301	1995-01-25	Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor	44481-5006-01
08/474,414	1995-06-07	Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor	44481-5006-02
08/486,673	1995-06-07	Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor	44481-5006-06
10/127,691	2002-04-23	Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor	44481-5006-09
09/035,135	1998-03-05	Process for production of inhibited forms of activated blood factors	44481-5007-04
09/801,089	2001-03-08	Modulation of integrin-mediated signal transduction	44481-5008-02
09/410,738	1999-10-01	Methods of screening for compounds that interact with human P _{2U2} purinergic receptor	44481-5010-02
09/947,922	2001-09-07	Methods of screening for compounds that interact with human P _{2U2} purinergic receptor	44481-5010-03
07/801,795	1991-12-02	Inhibitory immunoglobulin polypeptides to human PDGF beta receptor	44481-5017
08/253,440	1994-06-07	Inhibitory immunoglobulin polypeptides to human PDGF beta receptor	44481-5017-01
09/419,076	1999-10-15	Inhibitory immunoglobulin polypeptides to human PDGF beta receptor	44481-5017-04
09/585,410	2000-06-02	Inhibitory immunoglobulin polypeptides to human PDGF beta receptor	44481-5017-05
08/089,455	1993-07-09	Platelet glycoprotein V gene and uses	44481-5018
08/884,571	1997-06-27	Platelet glycoprotein V gene and uses	44481-5018-03
09/560,814	2000-04-28	Platelet glycoprotein V gene and uses	44481-5018-04

Schedule B, U.S. applications

Application No.	Filing Date	Title	Ref. No.
09/991,888	2001-11-26	Identification of Bap-1, a protein that binds to integrin and is Involved in integrin-mediated signal transduction	44481-5025-03
09/473,716	1999-12-29	Polynucleotides encoding a type V adenylyl cyclase	44481-5027-01
09/474,076	1999-12-29	Cloning and characterization of a human adenylyl cyclase	44481-5028-01
10/071,223	2002-02-11	Cloning and characterization of a human adenylyl cyclase	44481-5029-02
08/975,653	1997-11-21	Modulation of interactions between myosin and integrins	44481-5039-01
09/673,302	2001-03-23	Transgenic mammals expressing mutant GP IIIa	44481-5043
09/775,803	2001-02-05	Transgenic animals having a modified glycoprotein V gene	44481-5044
09/745,842	2000-12-26	P2Y12 receptor	44481-5053
08/948,672	1997-10-10	Selective Factor Xa inhibitors	44481-5012-01
09/500,231	2000-02-08	Selective Factor Xa inhibitors	44481-5015-02
09/664,535	2000-09-18	Benzamides and related inhibitors of Factor Xa	44481-5061-99
09/663,420	2000-09-15	Benzamides and related inhibitors of Factor Xa	44481-5061
10/126,976	2002-04-22	Benzamides and related inhibitors of Factor Xa	44481-5061-02
09/226,103	1999-01-07	Platelet ADP receptor inhibitors	44481-5042
09/501,370	2000-02-11	Alkenyl and alkynyl compounds as inhibitors of Factor Xa	44481-5045
09/501,371	2000-02-11	Inhibitors of Factor Xa	44481-5045-01
09/576,637	2000-05-24	Inhibitors of Factor Xa	44481-5046
09/576,634	2000-05-24	Inhibitors of Factor Xa	44481-5046-01
09/576,638	2000-05-24	Inhibitors of Factor Xa	44481-5047
09/577,131	2000-05-24	Inhibitors of Factor Xa	44481-5047-01
09/576,635	2000-05-24	Inhibitors of Factor Xa	44481-5048
09/576,636	2000-05-24	Inhibitors of Factor Xa	44481-5048-01
09/576,633	2000-05-24	Inhibitors of Factor Xa	44481-5049
09/576,632	2000-05-24	Inhibitors of Factor Xa	44481-5049-01
09/577,154	2000-05-24	Inhibitors of Factor Xa	44481-5049-02
09/636,804	2000-08-10	Inhibitors of Factor Xa	44481-5050

Schedule B, U.S. applications

Application No.	Filing Date	Title	Ref. No.
09/662,807	2000-09-15	Inhibitors of Factor Xa	44481-5051
09/794,214	2001-02-28	Inhibitors of Factor Xa	44481-5051-01
09/714,532	2000-11-17	β -Amino acid-, aspartic acid- and diaminopropionic -based inhibitors of Factor Xa	44481-5052
09/773,383	2001-02-01	Indole and benzimidazole inhibitors of Factor Xa	44481-5055
09/773,372	2001-02-01	Indalone and benzimidazolone inhibitors of Factor Xa	44481-5056
09/773,373	2001-02-01	3,4-Dihydro-2h-benzo[1,4]oxazine inhibitors of Factor Xa	44481-5057
09/773,374	2001-02-01	2-[1H]-Quinolone and 2-[1H]-quinoxalone inhibitors of Factor Xa	44481-5058
09/773,375	2001-02-01	Bivalent phenylene inhibitors of Factor Xa	44481-5059
09/775,812	2001-02-05	Platelet ADP receptor inhibitors	44481-5060
09/920,325	2001-08-02	Platelet ADP receptor inhibitors	44481-5060-01
09/816,782	2001-03-26	Oxindole inhibitors of Factor Xa	44481-5062
09/816,771	2001-03-26	Isoquinolone inhibitors of Factor Xa	44481-5063
09/816,781	2001-03-26	Bicyclic sulfonyl amino inhibitors of Factor Xa	44481-5064

Delaware

PAGE 1


The First State.

I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF OWNERSHIP, WHICH MERGES:

"COR THERAPEUTICS, INC.", A DELAWARE CORPORATION,

WITH AND INTO "MILLENNIUM PHARMACEUTICALS, INC." UNDER THE NAME OF "MILLENNIUM PHARMACEUTICALS, INC.", A CORPORATION ORGANIZED AND EXISTING UNDER THE LAWS OF THE STATE OF DELAWARE, AS RECEIVED AND FILED IN THIS OFFICE THE TWELFTH DAY OF FEBRUARY, A.D. 2002, AT 6 O'CLOCK P.M.

A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE NEW CASTLE COUNTY RECORDER OF DEEDS.



Harriet Smith Windsor
Harriet Smith Windsor, Secretary of State

2322355 8100M

AUTHENTICATION: 1610075

020093846

DATE: 02-12-02

CERTIFICATE OF OWNERSHIP AND MERGER

MERGING

COR THERAPEUTICS, INC.
(a Delaware corporation)

INTO

MILLENNIUM PHARMACEUTICALS, INC.
(a Delaware corporation)

Millennium Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the "Corporation"), does hereby certify:

FIRST: That the Corporation was incorporated on the 13th day of January, 1993, pursuant to the General Corporation Law of the State of Delaware.

SECOND: That the Corporation owns all of the outstanding shares of each class of the stock of COR Therapeutics, Inc., a corporation incorporated on the 4th day of February, 1988 pursuant to the General Corporation Law of the State of Delaware.

THIRD: That the Board of Directors of the Corporation, by written action in lieu of a meeting dated the 4th day of February, 2002, duly adopted the following resolutions:

RESOLVED: That, pursuant to Section 253 of the Delaware General Corporation Law, the Corporation is hereby authorized to merge COR Therapeutics, Inc., a Delaware corporation which is a wholly owned subsidiary of the Corporation, into the Corporation;

RESOLVED: That the President and Secretary of the Corporation be, and each of them hereby is, authorized to execute a Certificate of Ownership and Merger with respect to the merger of COR Therapeutics, Inc. into the Corporation, cause the same to be filed with the Secretary of State of the State of Delaware and take all such other actions and to execute all such other instruments and agreements as the officer or officers so acting may deem appropriate to effect such merger;

RESOLVED: That the merger of COR Therapeutics, Inc. into the Corporation shall be effective upon the filing of a Certificate of Ownership and Merger with the Secretary of State of the State of Delaware.

IN WITNESS WHEREOF, the Corporation has caused this Certificate to be signed by its authorized officer this 12th day of February, 2002.

MILLENNIUM
PHARMACEUTICALS, INC.

By: /s/ Mark J. Levin
Title: President



ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

RECEIVED
SEP 30 1994
POUCH MAIL

RECEIVED
SEP 19 1994
MORRISON & FOERSTER

RECORDATION FORM COVER SHEET PATENTS ONLY

U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

Any Dkt No: 228032000223

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):

Uma Sinha

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

2. Name and address of receiving party(ies):

Name: COR Therapeutics

Internal Address: So. San Francisco, California

Street Address: 256 E. Grand Avenue

City: So. San Francisco State: Calif. ZIP: 94080

Additional name(s) & address(es) attached? ☐ Yes ☒ No

3. Nature of conveyance: 19

☒ Assignment

☐ Merger

☐ Security Agreement

☐ Change of Name

☐ Other: _____

Execution Date: May 10, 1994

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is: June 29, 1994

A. Patent Application No.(s)

B. Patent No.(s)

Additional numbers attached? ☐ Yes ☒ No

5. Name and address of party to whom correspondence concerning document should be mailed:

MORRISON & FOERSTER

755 Page Mill Road

Palo Alto, CA 94304-1018

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"Express Mail" Mailing Label No. TR 361039140US

Date of Deposit June 29, 1994

I hereby certify that the document or file is being deposited with the United States Patent and Trademark Office to Address 37 CFR 1.10 on the date indicated above and to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

VIC BARRAHO
(Typed or Printed Name of Person Mailing Paper or File)

6. Total number of applications and patents involved: 1

7. Total fee (37 CFR 3.41): \$40.00

☐ Enclosed

☒ Authorized to be charged to deposit account

8. Deposit account number:

03-1952

(Attach duplicate copy of this page if paying by deposit account)

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document. 03-1952 030 581 40.00CH

Tyler Dylan

Name of Person Signing

Registration No. 37,612

Signature

Date

Total number of pages comprising cover sheet, attachments and document: 2

Mail documents to be recorded with required cover sheet information to:

Commissioner of Patents and Trademarks

Box Assignments

Washington, D.C. 20231

93562182 3

ML

ASSIGNMENT

THIS ASSIGNMENT, by UMA SINHA (hereinafter referred to as the assignor), residing at San Francisco, California, witnesseth:

WHEREAS, the said assignor has invented certain new and useful improvements in AGENTS AFFECTING THROMBOSIS AND HEMOSTASIS set forth in an application for Letters Patent of the United States, having an oath or declaration executed by me on even date herewith; and

WHEREAS, COR Therapeutics, a corporation duly organized under and pursuant to the laws of Delaware, and having its principal place of business at 256 E. Grand Avenue, South San Francisco, California 94080 (hereinafter referred to as the assignee) is desirous of acquiring the entire right, title and interest in and to said inventions and said application for Letters Patent of the United States, and in and to any Letters Patent or Patents, United States or foreign, to be obtained therefor and thereon:

NOW THEREFORE, in consideration of One Dollar (\$1.00) and other good and sufficient considerations, the receipt of which is hereby acknowledged, the said assignor has sold, assigned, transferred and set over, and by these presents does sell, assign, transfer and set over unto the said assignee, its successors, legal representatives and assigns, the entire right, title and interest in and to the above-mentioned inventions, application for Letters Patent and any and all Letters Patent or Patents in the United States of America and all foreign countries which may be granted therefor and thereon, and in and to any and all divisions, continuations, and continuations-in-part of said application, or reissues or extensions of said Letters Patent or Patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by the said assignee, for its own use and behoof and the use and behoof of its successors, legal representatives and assigns, to the full end of the term or terms for which Letters Patent or Patents may be granted, as fully and entirely as the same would have been held and enjoyed by the assignor, had this sale and assignment not been made.

AND for the same consideration, the said assignor hereby covenants and agrees to and with the said assignee, its successors, legal representatives and assigns that, at the time of the execution and delivery of these presents, the said assignor is the lawful owner of his entire right, title and interest in and to the said inventions and the application for Letters Patent above-mentioned, and that the same are unencumbered and that the said assignor has good and full right and lawful authority to sell and convey the same in the manner herein set forth.

AND for the same consideration, the said assignor hereby covenants and agrees to and with the said assignee, its successors, legal representatives and assigns, that the said assignor will, whenever counsel of the said assignee, or the counsel of its successors, legal representatives and assigns, shall advise that any proceeding in connection with said inventions, or said application for Letters Patent, or any proceeding in connection with Letters Patent for said inventions in any country, including interference proceedings, is lawful and desirable, or that any division, continuation or continuation-in-part of any application for Letters Patent or any reissue or extension of any Letters Patent, to be obtained thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for

REL 7079 R/W 650

the procurement, maintenance, enforcement and defense of Letters Patent for said inventions, without charge to said assignee, its successors, legal representatives and assigns, but at the cost and expense of the said assignee, its successors, legal representatives and assigns.

AND the said assignor hereby requests the Commissioner of Patents to issue said Letters Patent of the United States to the said assignee of the said inventions and the Letters Patent to be issued thereon for the sole use and behoof of the said assignee, its successors, legal representatives and assigns.

Date: 10 MAY 1994

Name of Inventor

Uma Sinha

UMA SINHA

Witnessed:

Paula B Conley

5/10/94

DATE

Witnessed:

Gella Aguilar

5/10/94

DATE


RECORDED
PATENT & TRADEMARK OFFICE

JUN 29 94

REEL 7079 FRAME 651



MORRISON & FOERSTER
TYLER DYLAN
755 PAGE MILL ROAD
PALO ALTO, CALIFORNIA 94304-1018



UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE U.S. PATENT AND TRADEMARK OFFICE ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT ASSIGNMENT PROCESSING SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT BRANCH, NORTH TOWER BUILDING, SUITE 10C35, WASHINGTON, D.C. 20231

ASSIGNOR:
WOLF, DAVID

DOC DATE: 05/10/94

RECORDATION DATE: 06/29/94 NUMBER OF PAGES 003 REEL/FRAME 7079/0652

DIGEST : ASSIGNMENT OF ASSIGNORS INTEREST

ASSIGNEE:
COR THERAPEUTICS
256 E. GRAND AVENUE
SO. SAN FRANCISCO, CALIFORNIA 94080

SERIAL NUMBER	8-268003	FILING DATE	06/29/94
PATENT NUMBER		ISSUE DATE	00/00/00

EXAMINER/PARALEGAL
ASSIGNMENT BRANCH
ASSIGNMENT/CERTIFICATION SERVICES DIVISION

P12973
DOCKETED LGA
2803-0002,23

RECEIVED

SEP 19 1994

MORRISON & FOERSTER

ASSIGNMENT

THIS ASSIGNMENT, by DAVID WOLF (hereinafter referred to as the assignor), residing at Palo Alto, California, witnesseth:

WHEREAS, the said assignor has invented certain new and useful improvements in AGENTS AFFECTING THROMBOSIS AND HEMOSTASIS set forth in an application for Letters Patent of the United States, having an oath or declaration executed by me on even date herewith; and

WHEREAS, COR Therapeutics, a corporation duly organized under and pursuant to the laws of Delaware, and having its principal place of business at 256 E. Grand Avenue, South San Francisco, California 94080 (hereinafter referred to as the assignee) is desirous of acquiring the entire right, title and interest in and to said inventions and said application for Letters Patent of the United States, and in and to any Letters Patent or Patents, United States or foreign, to be obtained therefor and thereon:

NOW THEREFORE, in consideration of One Dollar (\$1.00) and other good and sufficient considerations, the receipt of which is hereby acknowledged, the said assignor has sold, assigned, transferred and set over, and by these presents does sell, assign, transfer and set over unto the said assignee, its successors, legal representatives and assigns, the entire right, title and interest in and to the above-mentioned inventions, application for Letters Patent and any and all Letters Patent or Patents in the United States of America and all foreign countries which may be granted therefor and thereon, and in and to any and all divisions, continuations, and continuations-in-part of said application, or reissues or extensions of said Letters Patent or Patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by the said assignee, for its own use and behoof and the use and behoof of its successors, legal representatives and assigns, to the full end of the term or terms for which Letters Patent or Patents may be granted, as fully and entirely as the same would have been held and enjoyed by the assignor, had this sale and assignment not been made.

AND for the same consideration, the said assignor hereby covenants and agrees to and with the said assignee, its successors, legal representatives and assigns that, at the time of the execution and delivery of these presents, the said assignor is the lawful owner of his entire right, title and interest in and to the said inventions and the application for Letters Patent above-mentioned, and that the same are unencumbered and that the said assignor has good and full right and lawful authority to sell and convey the same in the manner herein set forth.


AND for the same consideration, the said assignor hereby covenants and agrees to and with the said assignee, its successors, legal representatives and assigns, that the said assignor will, whenever counsel of the said assignee, or the counsel of its successors, legal representatives and assigns, shall advise that any proceeding in connection with said inventions, or said application for Letters Patent, or any proceeding in connection with Letters Patent for said inventions in any country, including interference proceedings, is lawful and desirable, or that any division, continuation or continuation-in-part of any application for Letters Patent or any reissue or extension of any Letters Patent, to be obtained thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for

the procurement, maintenance, enforcement and defense of Letters Patent for said inventions, without charge to said assignee, its successors, legal representatives and assigns, but at the cost and expense of the said assignee, its successors, legal representatives and assigns.

AND the said assignor hereby requests the Commissioner of Patents to issue said Letters Patent of the United States to the said assignee of the said inventions and the Letters Patent to be issued thereon for the sole use and behoof of the said assignee, its successors, legal representatives and assigns.

Date: 10 MAY 1994

Name of Inventor



DAVID WOLF

Witnessed:



10 May 1994
DATE

Witnessed:



May 10, 1994
DATE